

ASTERAND PLC
(‘Asterand’ or ‘the Company’)

Notification of Investor Evening

Date:	19 October 2010
Time:	5.15pm for 5.30pm start – followed by wine canapés
Venue:	Buchanan Communications, 45 Moorfields, London EC2Y 9AE

Asterand plc (LSE: ATD), (“Asterand” or the “Company”), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, is pleased to announce that it will host an investor evening on 19 October 2010 at the offices of Buchanan Communications.

The event will provide private investors and potential shareholders with an opportunity to participate in a Q&A session with Asterand’s Management team, headed by Martyn Coombs, Chief Executive Officer and John Stchur, Chief Financial Officer, Victoria Blanc, VP Government Affairs, Amanda Woodrooffe, PhD, General Manager and its recently appointed Chief Scientific Officer, Dalia Cohen.

Included in the evening’s presentation Asterand will outline its strategy and performance and will also provide detail on its recent contract win from the US National Cancer Institute that has been awarded over a 5-year period and worth up to \$24.3 million.

If you would like to attend the event, please contact Alicia Chapman at Buchanan Communications either via e-mail aliciac@buchanan.uk.com or via telephone on 020 7466 5000

- Ends -

Contacts:

Asterand plc

Martyn Coombs, Chief Executive Officer
John Stchur, Chief Financial Officer

Tel: (313) 263-0960
As above

Buchanan Communications

Lisa Baderoon / Mark Court / Isabel Podda

Tel: +44 (0) 20 7466 5000

Daniel Stewart & Company plc

Martin Lampshire

Tel: +44 (0) 20 7776 6550

ABOUT ASTERAND

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one Company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the clinic.